

Edgar Filing: CYTODYN INC - Form 8-K

CYTODYN INC
Form 8-K
January 07, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 of 15(d) of the
Securities Exchange Act of 1934

January 3, 2011

Date of Report (date of earliest event reported)

CYTODYN INC.

Exact name of Registrant as Specified in its Charter

| | | |
|---|---------------------------|---------------------------------------|
| Colorado | 000-49908 | 75-3056237 |
| ----- | ----- | ----- |
| State or Other Jurisdiction of Incorporation | Commission File Number | IRS Employer Identification Number |

1511 Third Street, Santa Fe, New Mexico 87505

Address of Principal Executive Offices, Including Zip Code

(505) 988-5520

Registrant's Telephone Number, Including Area Code

Not applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CYTODYN INC - Form 8-K

ITEM 8.01 OTHER EVENTS

On January 3, 2011 the Company hired Richard Trauger, PhD. as Director of Scientific Information.

Dr. Trauger received his Ph.D. in 1986 from the University Of South Carolina School Of Medicine in retrovirology. After completing his post-doctoral studies at the Scripps Research Institute in La Jolla, Dr Trauger joined The Immune Response Corporation as Associate Director of Immunology, where he worked with Dr. Jonas Salk on the development of an immune-based therapy for HIV infection. In addition to his research duties, Dr. Trauger also functioned as the company's Scientific Liaison and was the company's point of contact to the scientific, financial and activist communities.

The Company issued a press release on January 7, 2011 (attached hereto as Exhibit 99) regarding new hire Richard Trauger

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

- (a) Financial Statements of Businesses Acquired.

Not Applicable.

- (b) Pro Forma Financial Information

Not Applicable.

- (c) Shell Company Transactions

Not Applicable.

- (d) Exhibits

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTODYN INC.

Date: January 7, 2011

By: /s/ Kenneth J. Van Ness

Kenneth J. Van Ness
President and CEO